Difference between revisions of "Citalopram-fluvoxamine"

From Psychiatrienet
Jump to: navigation, search
Line 2: Line 2:
 
| from = citalopram
 
| from = citalopram
 
| to = fluvoxamine
 
| to = fluvoxamine
| stop =  
+
| stop = {{StopCitalopramAtDose}}
* Gradually reduce dosage of citalopram/escitalopram to a maximum of 20 mg/ day resp. 10 mg/day, when this dosage is respectively > 20 mg/day and > 10 mg/day.
 
* When a dosage of 20 mg/day, resp. 10 mg/day, is reached, stop administration.
 
 
| start =  
 
| start =  
 
* No wash-out period is needed.
 
* No wash-out period is needed.
 
* Start fluvoxamine the next day in normal dosage of 50 mg/day.
 
* Start fluvoxamine the next day in normal dosage of 50 mg/day.
 
| info =  
 
| info =  
* The same applies to [[escitalopram]].
 
 
* {{theorSS}}
 
* {{theorSS}}
* Fluvoxamine slows the metabolism of (es)citalopram by inhibition of CYP2C19 and CYP3A4
+
* Fluvoxamine slows the metabolism of citalopram by inhibition of CYP2C19 and CYP3A4
 
}}
 
}}

Revision as of 22:14, 4 March 2010

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from citalopram to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop citalopram
  • Gradually reduce dosage of citalopram to a maximum of 20 mg/day, when this dosage is > 20 mg/day.
  • When a dosage of 20 mg/day is reached, stop administration.
Eenrichtingbord.png Start fluvoxamine
  • No wash-out period is needed.
  • Start fluvoxamine the next day in normal dosage of 50 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluvoxamine slows the metabolism of citalopram by inhibition of CYP2C19 and CYP3A4
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.